Description Anti-EGFL7 is a humanized antibody against EGFL7 (Epidermal Growth Factor Domain-Like 7). EGFL7 is a vascular-restricted secreted protein present in the tracks that surround tumor blood vessels, supporting their survival. Anti-EGFL7 antibody reduces tumor vascular function and is designed to inhibit tumor growth.
Development Status
A Phase I trial evaluating anti-EGFL7 in combination with Avastin® (bevacizumab) for solid tumors is ongoing. Phase II studies evaluating anti-EGFL7 for first-line metastatic non-squamous non-small cell lung cancer and metastatic colorectal cancer are ongoing or planned.
For Avastin full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.avastin.com.
Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.
National Institutes of Health Website: www.clinicaltrials.gov
July 2011